stroke, ischemic stroke, and damages caused by surgery, and wherein said human is one having such an injury.

4 (Thrice-Amended). A method in accordance with claim 16, wherein said method is for ameliorating the degenerative effects on the central nervous system or the peripheral nervous system of a disease selected from the group consisting of diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency, and wherein said human is one having such a disease.

5 (Thrice-Amended). A method in accordance with claim 16, wherein said method is for ameliorating the degenerative effects of a disease on the central nervous system or the peripheral nervous system, wherein said disease is other than an autoimmune disease or a neoplasm, and wherein said human is one having such disease.

Rewrite amended claim 16 in twice-amended form as follows:

16 (Twice-amended). A method of ameliorating the degenerative effects of injury or disease on the central nervous system or peripheral nervous system, by preventing or inhibiting axonal degeneration and/or promoting nerve

regeneration, wherein said injury or disease is other than an autoimmune disease or a neoplasm, comprising administering to a human having such an injury or disease an effective amount for neuroprotection of a composition comprising an agent selected from the group consisting of:

(a) non-recombinant, NS-specific antiself activated T-cells;

(b) a NS-specific antigen or a derivative thereof;

(c) a peptide derived from a NS-specific antigen or a derivative thereof;

(d) a nucleotide sequence encoding a NS-specific antigen;

(e) a nucleotide sequence encoding a peptide derived from a NS-specific antigen; and

(f) any combination of (a)-(e).

Delete claim 10 and substitute therefor new claim 20 as follows:

20 (New). The method according to claim 17 in which said NS-specific antigen is administered concurrently with administration of the composition comprising an agent of (a), (c), (d) or (e).